Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536392 · ClinicalTrials.gov registry record · Phase 3
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 76
- Enrollment target
NCT01536392: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT01536392 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01536392, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 76 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare granisetron (when given through a patch) to ondansetron (when taken by mouth) for reducing nausea and vomiting in women with cervical, endometrial, or vaginal cancer having chemoradiation. Granisetron and ondansetron are designed to help reduce nausea and vomiting.
Interventions
- BEHAVIORAL Questionnaires
- DRUG Ondansetron
- DRUG Granisetron
- BEHAVIORAL Study Drug Diary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2012-03 |
| Est. Completion | 2019-10-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01536392
The ClinicalTrials.gov registry entry for NCT01536392 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Questionnaires is the first listed.
NCT01536392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01536392 about?
NCT01536392 is a clinical study titled "Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation". The goal of this clinical research study is to compare granisetron (when given through a patch) to ondansetron (when taken by mouth) for reducing nausea and vomiting in women with cervical, endometrial, or vaginal cancer having chemoradiation. Granisetron and ondansetron are designed to help reduce...
What is the current status of trial NCT01536392?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 76 participants. The study started on 2012-03. Estimated completion is 2019-10-03.
What interventions are being tested in trial NCT01536392?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Ondansetron (DRUG), Granisetron (DRUG), Study Drug Diary (BEHAVIORAL).
Who is sponsoring clinical trial NCT01536392?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.